Attovia Therapeutics, Inc. Common Stock (ATTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Attovia Therapeutics, Inc. Common Stock (ATTO) has a cash flow conversion efficiency ratio of -0.149x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.79 Million) by net assets ($112.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Attovia Therapeutics, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
Attovia Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Attovia Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Attovia Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Attovia Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See ATTO operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baltic Classifieds Group PLC
LSE:BCG
|
0.103x |
|
Coretronic
TWO:5371
|
0.090x |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
|
0.005x |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
0.014x |
|
Garcia Reguera S.A.
BA:REGE
|
-0.126x |
|
NATURENERGIE
SW:NEAG
|
0.173x |
|
SP Setia Bhd
KLSE:8664
|
0.035x |
|
Piedmont Office Realty Trust Inc
NYSE:PDM
|
0.040x |
Annual Cash Flow Conversion Efficiency for Attovia Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. View Attovia Therapeutics, Inc. Common Stock (ATTO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $150.79 Million | $-59.20 Million | -0.393x | +30.38% |
| 2024-12-31 | $62.13 Million | $-35.03 Million | -0.564x | -- |
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more